A molecular modeling study of novel aldose reductase (AR) inhibitors

Auwal Muhammad; Kanikar Muangchoo; Ibrahim A. Muhammad; Ya'u S. Ajingi; Aliyu M. Bello; Ibrahim Y. Muhammad; Tasi'u A. Mika'il; Rakiya Aliyu; Auwal Muhammad; Kanikar Muangchoo; Ibrahim A. Muhammad; Ya'u S. Ajingi; Aliyu M. Bello; Ibrahim Y. Muhammad; Tasi'u A. Mika'il; Rakiya Aliyu

doi:10.3934/biophy.2020026

AIMS Biophysics

2020, Volume 7, Issue 4: 380-392. doi: 10.3934/biophy.2020026

Previous Article Next Article

Research article Special Issues

A molecular modeling study of novel aldose reductase (AR) inhibitors

1.
Department of Physics, Faculty of Science, Kano University of Science and Technology (KUST), Wudil, Kano, Nigeria
2.
Faculty of Science and Technology, Rajamangala University of Technology Phranakhon (RMUTP), Bang Sue, Bangkok, Thailand
3.
Department of Biochemistry, Faculty of Science, Kano University of Science and Technology (KUST), Wudil, Kano, Nigeria
4.
Department of Biology, Faculty of Science, Kano University of Science and Technology (KUST), Wudil, Nigeria
5.
Department of Biochemistry, Faculty of Basic Medical Sciences, Bayero University Kano (BUK), Kano, Nigeria

Received: 11 July 2020 Accepted: 20 September 2020 Published: 25 September 2020

Aldose reductase (AR) is an enzyme of the polyol pathway implicated in long-term effect of diabetes mellitus. The development of new molecules as drugs for the inhibition of this enzyme is a growing area of research. Several in vivo and in vitro studies have been carried out to test the inhibitory effect of many organic compounds against AR, but the results have been limited due to their weak pharmacokinetic parameters and safety profile. In this study, molecular docking and molecular dynamics (MD) simulation were performed to establish the inhibitory effect of two critical bioactive compounds (astaxanthin and zeaxanthin) that were affirmed to be safe and powerful antioxidants. Docking studies revealed that both astaxanthin and zeaxanthin displays good binding affinity and inhibition to AR with binding energies of −5.88 kcal/mol and −5.63 kcal/mol, respectively. In contrast to epalrestat; the standard inhibitor having a binding energy of −5.62 kcal/mol. Amino acid residue analysis has shown that both compounds, including the standard inhibitor, bind to the same site due to their common interaction with Trp20 and Tyr48 at AR catalytic site. To complement molecular docking results, we performed MD simulations. The results show that the binding energies of the standard inhibitor, astaxanthin, and zeaxanthin are −134.3486 kJ/mol, −186.271 kJ/mol, and −123.557 kJ/mol, respectively. In both cases, astaxanthin displays better inhibition to AR followed by the standard inhibitor and zeaxanthin.
- aldose reductase,
- bioactive compounds,
- binding energy,
- molecular docking,
- molecular dynamics
Citation: Auwal Muhammad, Kanikar Muangchoo, Ibrahim A. Muhammad, Ya'u S. Ajingi, Aliyu M. Bello, Ibrahim Y. Muhammad, Tasi'u A. Mika'il, Rakiya Aliyu. A molecular modeling study of novel aldose reductase (AR) inhibitors[J]. AIMS Biophysics, 2020, 7(4): 380-392. doi: 10.3934/biophy.2020026

Related Papers:

Abstract

Aldose reductase (AR) is an enzyme of the polyol pathway implicated in long-term effect of diabetes mellitus. The development of new molecules as drugs for the inhibition of this enzyme is a growing area of research. Several in vivo and in vitro studies have been carried out to test the inhibitory effect of many organic compounds against AR, but the results have been limited due to their weak pharmacokinetic parameters and safety profile. In this study, molecular docking and molecular dynamics (MD) simulation were performed to establish the inhibitory effect of two critical bioactive compounds (astaxanthin and zeaxanthin) that were affirmed to be safe and powerful antioxidants. Docking studies revealed that both astaxanthin and zeaxanthin displays good binding affinity and inhibition to AR with binding energies of −5.88 kcal/mol and −5.63 kcal/mol, respectively. In contrast to epalrestat; the standard inhibitor having a binding energy of −5.62 kcal/mol. Amino acid residue analysis has shown that both compounds, including the standard inhibitor, bind to the same site due to their common interaction with Trp20 and Tyr48 at AR catalytic site. To complement molecular docking results, we performed MD simulations. The results show that the binding energies of the standard inhibitor, astaxanthin, and zeaxanthin are −134.3486 kJ/mol, −186.271 kJ/mol, and −123.557 kJ/mol, respectively. In both cases, astaxanthin displays better inhibition to AR followed by the standard inhibitor and zeaxanthin.

Acknowledgments

The second author was financially supported by Rajamangala University of Technology Phra Nakhon (RMUTP) research scholarship.

Conflicts of interest

The authors declare that there are no conflicts of interest related to this study.

References

[1]	Badria FA, Elimam DM, Elabshihy MSI, et al. Aldose reductase inhibitors from nature: A new hope for treatment of cataract .
[2]	Chethan S, Dharmesh SM, Malleshi NG (2008) Inhibition of aldose reductase from cataracted eye lenses by finger millet (Eleusine coracana) polyphenols. Bioorgan Med Chem 16: 10085-10090.
[3]	Kyselova Z, Stefek M, Bauer V (2004) Pharmacological prevention of diabetic cataract. J Diabetes Complicat 18: 129-140.
[4]	Wang Z, Ling B, Zhang R, et al. (2009) Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase. J Mol Graph Model 28: 162-169.
[5]	Ribaya-Mercado JD, Blumberg JB (2004) Lutein and zeaxanthin and their potential roles in disease prevention. J Am Coll Nutr 23: 567S-587S.
[6]	Yu B, Wang J, Suter PM, et al. (2012) Spirulina is an effective dietary source of zeaxanthin to humans. Brit J Nutr 108: 611-619.
[7]	Ekpe L, Inaku K, Ekpe V (2018) Antioxidant effects of astaxanthin in various diseases—A review. J Mol Pathophysiol 7: 1-6.
[8]	Yang M, Chen Y, Zhao T, et al. (2020) Effect of astaxanthin on metabolic cataract in rats with type 1 diabetes mellitus. Exp Mol Pathol 113: 104372.
[9]	Ishikawa S, Hashizume K, Nishigori H, et al. (2015) Effect of astaxanthin on cataract formation induced by glucocorticoids in the chick embryo. Curr Eye Res 40: 535-540.
[10]	Benlarbi-Ben Khedher M, Hajri K, Dellaa A, et al. (2019) Astaxanthin inhibits aldose reductase activity in Psammomys obesus, a model of type 2 diabetes and diabetic retinopathy. Food Sci Nutr 7: 3979-3985.
[11]	Du X, Li Y, Xia YL, et al. (2016) Insights into protein–ligand interactions: mechanisms, models, and methods. Int J Mol Sci 17: 144.
[12]	Olsson TS, Williams MA, Pitt WR, et al. (2008) The thermodynamics of protein–ligand interaction and solvation: insights for ligand design. J Mol Biol 384: 1002-1017.
[13]	Bronowska AK (2011) Thermodynamics of ligand-protein interactions: implications for molecular design. Thermodynamics-Interaction Studies-Solids, Liquids and Gases IntechOpen.
[14]	Martin SF, Clements JH (2013) Correlating structure and energetics in protein-ligand interactions: paradigms and paradoxes. Annu Rev Biochem 82: 267-293.
[15]	Martis EAF, Coutinho EC (2019) Free energy-based methods to understand drug resistance mutations. Structural Bioinformatics: Applications in Preclinical Drug Discovery Process Springer, 1-24.
[16]	Kim S, Thiessen PA, Bolton EE, et al. (2016) PubChem substance and compound databases. Nucleic Acids Res 44: D1202-D1213.
[17]	Hanwell MD, Curtis DE, Lonie DC, et al. (2012) Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminformatics 4: 17.
[18]	Bohren KM, Brownlee JM, Milne AC, et al. (2005) The structure of Apo R268A human aldose reductase: hinges and latches that control the kinetic mechanism. (BBA)-Proteins Proteom 1748: 201-212.
[19]	Morris GM, Huey R, Lindstrom W, et al. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791.
[20]	Laskowski RA, Swindells MB (2011) LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51: 2778-2786.
[21]	Abraham MJ, Murtola T, Schulz R, et al. (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1: 19-25.
[22]	Schmid N, Eichenberger AP, Choutko A, et al. (2011) Definition and testing of the GROMOS force-field versions 54A7 and 54B7. Eur Biophys J 40: 843.
[23]	Mark P, Nilsson L (2001) Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. J Phys Chem A 105: 9954-9960.
[24]	Stroet M, Caron B, Visscher KM, et al. (2018) Automated topology builder version 3.0: Prediction of solvation free enthalpies in water and hexane. J Chem Theory Comput 14: 5834-5845.
[25]	Darden T, York D, Pedersen L (1993) Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089-10092.
[26]	Berendsen HJC, Postma JPM, van Gunsteren WF, et al. (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81: 3684-3690.
[27]	Martonák R, Laio A, Parrinello M (2003) Predicting crystal structures: the Parrinello-Rahman method revisited. Phys Rev Lett 90: 075503.
[28]	Humphrey W, Dalke A, Schulten K (1996) VMD: Visual molecular dynamics. J Mol Graph 14: 33-38.
[29]	Kumari R, Kumar R, Consortium OSDD, et al. (2014) g_mmpbsa—A GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 54: 1951-1962.
[30]	Duan LL, Feng GQ, Zhang QG (2016) Large-scale molecular dynamics simulation: Effect of polarization on thrombin-ligand binding energy. Sci Rep 6: 31488.
[31]	Ren J, Yuan X, Li J, et al. (2020) Assessing the performance of the g_mmpbsa tools to simulate the inhibition of oseltamivir to influenza virus neuraminidase by molecular mechanics Poisson–Boltzmann surface area methods. J Chin Chem Soc 67: 46-53.
[32]	Lee HS, Jo S, Lim H-S, et al. (2012) Application of binding free energy calculations to prediction of binding modes and affinities of MDM2 and MDMX inhibitors. J Chem Inf Model 52: 1821-1832.
[33]	Umamaheswari M, Aji C, Kuppusamy A, et al. (2012) In silico docking studies of aldose reductase inhibitory activity of selected flavonoids. Int J Drug Dev Res 4: 328-334.
[34]	Khan S, Bhardwaj T, Somvanshi P, et al. (2018) Inhibition of C298S mutant of human aldose reductase for antidiabetic applications: Evidence from in silico elementary mode analysis of biological network model. J Cell Biochem 119: 6961-6973.
[35]	Naeem S, Hylands P, Barlow D (2013) Docking studies of chlorogenic acid against aldose redutcase by using molgro virtual Docker software. J Appl Pharm Sci 3: 13-20.
[36]	Padmaja S, MP, Raju TN (2016) Molecular docking studies of Hemidesmus indicus plant derived compounds as aldose reductase inhibitors. Int J Pharm Sci Rev Res 37: 92-95.

Reader Comments

Your name:*

Email:*
© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)